ArticleDiabetes care2021

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.

Geremia B Bolli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.